- Home
- KZR vs BSX Comparison
KZR vs BSX Comparison
Compare KZR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- BSX
- Stock Information
- Founded
- KZR 2015
- BSX 1979
- Country
- KZR United States
- BSX United States
- Employees
- KZR N/A
- BSX N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- BSX Medical/Dental Instruments
- Sector
- KZR Health Care
- BSX Health Care
- Exchange
- KZR Nasdaq
- BSX Nasdaq
- Market Cap
- KZR 29.7M
- BSX 157.6B
- IPO Year
- KZR 2018
- BSX 1992
- Fundamental
- Price
- KZR $3.74
- BSX $98.50
- Analyst Decision
- KZR Hold
- BSX Strong Buy
- Analyst Count
- KZR 2
- BSX 22
- Target Price
- KZR $9.00
- BSX $118.91
- AVG Volume (30 Days)
- KZR 30.5K
- BSX 7.8M
- Earning Date
- KZR 11-11-2025
- BSX 10-22-2025
- Dividend Yield
- KZR N/A
- BSX N/A
- EPS Growth
- KZR N/A
- BSX 36.90
- EPS
- KZR N/A
- BSX 1.68
- Revenue
- KZR N/A
- BSX $18,494,000,000.00
- Revenue This Year
- KZR N/A
- BSX $19.75
- Revenue Next Year
- KZR N/A
- BSX $11.03
- P/E Ratio
- KZR N/A
- BSX $58.59
- Revenue Growth
- KZR N/A
- BSX 21.44
- 52 Week Low
- KZR $3.62
- BSX $80.64
- 52 Week High
- KZR $9.18
- BSX $109.50
- Technical
- Relative Strength Index (RSI)
- KZR 35.98
- BSX 28.49
- Support Level
- KZR $3.76
- BSX $104.24
- Resistance Level
- KZR $4.05
- BSX $109.50
- Average True Range (ATR)
- KZR 0.13
- BSX 2.11
- MACD
- KZR -0.01
- BSX -1.00
- Stochastic Oscillator
- KZR 6.82
- BSX 8.52
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.